
EyePoint Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€48.08M - Cost of goods sold
€3.22M - Gross profit
€44.86M - SG&A expenses
€44.91M - R&D expenses
€138.40M - EBITDA
-€130.74M - D&A
€1.49M - EBIT
-€138.46M - Interest expenses
€12.01K - EBT
-€125.86M - Tax expenses
€77.22K - Net income
-€125.94M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€28.33M - Changes in working capital
-€1.11M - Operating cash flow
-€127.13M - Capex
€2.69M - Other investing cash flow
-€133.29M - Net investing cash flow
-€172.15M - Total cash dividends paid
€0.00 - Issuance of common stock
€136.21M - Debt repayment
-€120.12K - Other financing cash flow
€9.93M - Net financing cash flow
€139.82M - Foreign exchange effects
€0.00 - Net change in cash
-€159.34M - Cash at end of period
€73.19M - Free cash flow
-€124.45M
Balance sheet
- Cash and cash equivalents
€73.07M - Cash and short-term investments
€273.01M - Total receivables
€379.24K - Inventory
€1.83M - Other current assets
€5.34M - Total current assets
€280.55M - Property, plant & equipment
€25.36M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€5.17M - Total non-current assets
€30.53M - Total assets
€311.08M - Accounts payable
€14.09M - Short-term debt
€1.52M - Other current liabilities
€15.77M - Total current liabilities
€35.76M - Long-term debt
€19.15M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€151.87K - Total non-current liabilities
€19.30M - Total liabilities
€55.06M - Common stock
€59.20K - Retained earnings
-€787.83M - Other equity
€791.93K - Total equity
€256.02M - Total liabilities and shareholders' equity
€311.08M
Company information
- Market capitalization
€565.80M - Employees
165 - Enterprise Value
€545.16M
Company ratios
- Gross margin
-
93.3% Much worse than peer group: 1,569,383,908,285,939,400.0% - EBITDA margin
-
-271.9% Much worse than peer group: 10,655,874,544,827,208,000.0% - EBIT margin
-
-287.9% Much worse than peer group: 3,610,547,788,176,909,000.0% - EBT margin
-
-261.8% Much worse than peer group: 10,940,544,724,014,755,000.0% - Net margin
-
-261.9% Much worse than peer group: 10,958,360,016,292,917,000.0% - ROE
-
-49.2% Much better than peer group: -181.8% - ROA
-
-40.5% Much better than peer group: -165.0% - Asset turnover
-
15.5% Worse than peer group: 34.2% - FCF margin
-
-270.0% Much better than peer group: -6,018,246,406,126,677,600.0% - FCF yield
-22.9% - Efficiency ratio
371.9% - Net sales per employee
-
€291.42K - Net income per employee
-
-€763.26K